Related Experiment Video
Updated: Jul 31, 2026
10:19
Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
Published on: August 9, 2012
Phenobarbital use and bladder cancer risk
J E Castelao1, M Gago-Dominguez, J M Yuan
1Department of Preventive Medicine, USC/Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90089-9175, USA. castelao@hsc.usc.edu
European Journal of Epidemiology
|September 4, 2003
Summary
Phenobarbital (PB) use does not appear to protect against bladder cancer. This study found no association between PB use and reduced bladder cancer risk in the general population.
Area of Science:
- Epidemiology
- Oncology
- Pharmacology
Background:
- Previous studies suggested phenobarbital (PB) use might protect against bladder cancer.
- This protective effect was hypothesized to stem from PB inducing detoxification enzymes for carcinogens in cigarette smoke.
Purpose of the Study:
- To investigate the association between phenobarbital (PB) use and bladder cancer risk.
- To determine if PB has a protective role in bladder cancer development.
Main Methods:
- A population-based case-control study was conducted in Los Angeles.
- 815 bladder cancer cases and 815 matched controls were interviewed regarding lifetime PB use.
Main Results:
- Ever use of PB showed no association with bladder cancer risk (OR: 0.86; 95% CI: 0.54, 1.39).
- Regular PB use also did not correlate with bladder cancer risk in men, women, smokers, or non-smokers.
- Highest PB consumption was linked to a non-significant increased risk (OR: 2.46; 95% CI: 0.90, 6.78).
Conclusions:
- This study did not find evidence supporting a protective role for phenobarbital (PB) in bladder cancer development.
- The findings do not support the hypothesis that PB use reduces bladder cancer incidence in the general population.
More Related Videos
Related Concept Videos
01:14CNS Depressants: Barbiturates and Benzodiazepines
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
01:29Anxiolytic Drugs: Benzodiazepines and Buspirone
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
01:20Sedatives and Hypnotics Drugs: Barbiturates
Sedatives and hypnotics encompass a drug class that acts on the central nervous system (CNS) to alleviate anxiety, promote relaxation and induce sleep.These drugs function by amplifying the actions of the neurotransmitter γ-aminobutyric acid (GABA), resulting in reduced neuronal activity. Barbiturates, a subset of sedatives and hypnotics first synthesized in the late 1800s, are categorized into ultra-short, short, intermediate, and long-acting groups based on their duration of effect. A key...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...